Provided by Tiger Trade Technology Pte. Ltd.

Galmed Pharmaceuticals

0.6900
+0.01001.47%
Volume:1.78K
Turnover:1.23K
Market Cap:3.78M
PE:-0.20
High:0.6900
Open:0.6900
Low:0.6900
Close:0.6800
52wk High:3.50
52wk Low:0.5900
Shares:5.48M
Float Shares:2.02M
Volume Ratio:0.42
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4400
EPS(LYR):-8.0757
ROE:-46.34%
ROA:-20.90%
PB:0.20
PE(LYR):-0.09

Loading ...

Galmed Pharmaceuticals Sets March 4 Vote on Reverse Stock Split to Address Nasdaq Listing Deficiency

TIPRANKS
·
17 hours ago

Galmed Pharmaceuticals Receives Nasdaq Minimum Bid Price Deficiency Notice

TIPRANKS
·
Jan 31

Galmed Pharmaceuticals Faces Nasdaq Delisting Risk Over Minimum Bid Price

Reuters
·
Jan 31

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

THOMSON REUTERS
·
Jan 31

Galmed Pharmaceuticals Announces Phase 1/2 Study of Aramchol and Regorafenib in Liver Cancer

Reuters
·
Dec 08, 2025

Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for Mash

THOMSON REUTERS
·
Dec 04, 2025

Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment

Reuters
·
Dec 04, 2025

Galmed Pharmaceuticals Reports Strong Cash Position and Expands Therapeutic Focus

Reuters
·
Dec 01, 2025

Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate

Benzinga
·
Nov 26, 2025

Galmed Pharmaceuticals Q3 2025 cash and equivalents up 25% to USD 19.2 million

Reuters
·
Nov 26, 2025

Press Release: Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
Nov 26, 2025

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)

TIPRANKS
·
Nov 19, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Energizer Holdings, Target

Reuters
·
Nov 19, 2025

BUZZ-Galmed Pharma rises after positive results of liver drug formulation study

Reuters
·
Nov 18, 2025

Galmed Pharmaceuticals Shares Rise 7.4% After Co Reports Liver Drug Trial Data

THOMSON REUTERS
·
Nov 18, 2025

BRIEF-Galmed Announces Meaningful Top Line Results From Am-001 Study Of Aramchol Meglumine

Reuters
·
Nov 18, 2025

Galmed Reports Strong Bioavailability Results for Aramchol Meglumine in Phase 1 Study

Reuters
·
Nov 18, 2025

Galmed Pharmaceuticals- Top-Line Results Showed That Bioavailability of Aramchol Meglumine 400Mg and 200Mg Granules Is Considerably Greater

THOMSON REUTERS
·
Nov 18, 2025

Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study

TIPRANKS
·
Nov 17, 2025

BRIEF-Galmed Announces Top-Line Results In Oncology MoA Studies A 3-Drug Combination Of Aramchol, Stivarga® And Metformin Significantly Enhanced Gi Tumor Cells, Killing In-Vivo And In-Vitro

Reuters
·
Nov 17, 2025